10-Q: Yubo International Biotech Reports Continued Losses

Yubo International Biotech Limited's Q3 2026 10-Q filing reveals persistent revenue absence and increased net loss, raising substantial doubt about its going concern status.

Summary

• Yubo International Biotech Limited reported no sales for the three and nine months ended September 30, 2026, resulting in zero gross profit.
• Operating expenses decreased by 34.4% to $203,388 for Q3 2026 and by 18.9% to $731,522 for the first nine months of 2026 compared to the prior year periods.
• The company incurred a net loss of $203,726 for Q3 2026 and $767,473 for the first nine months of 2026.
• As of September 30, 2026, the company had $9,465 in cash and a negative working capital of $2,970,075.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to recurring operating losses and insufficient revenue.
• A financial support letter was obtained from the largest shareholder, Jun Wang, to provide financial support for 12 months from November 10, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the continued lack of revenue, significant operating losses, and substantial doubt about the company's ability to continue as a going concern, despite a shareholder support letter.

Positives

• Operating expenses were reduced by 34.4% for the three-month period and 18.9% for the nine-month period compared to the prior year.
• A financial support letter from the largest shareholder provides a 12-month commitment to meet liabilities.
• The company is actively exploring more effective sales approaches and distribution channels.

Negatives

• No revenue was generated in the three or nine months ended September 30, 2026.
• The company reported a net loss of $203,726 for Q3 2026 and $767,473 for the first nine months of 2026.
• Significant negative working capital of $2,970,075 as of September 30, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern.
• The VIE structure carries inherent risks related to PRC regulations and enforceability of contractual arrangements.
• The company has not yet established an ongoing source of revenues and cash flows sufficient to cover its operating costs.

Risks

• The PRC government may find the VIE contractual arrangements non-compliant, leading to severe penalties or loss of interests.
• Changes in PRC laws and regulations could adversely affect the company's operations and ability to consolidate VIE results.
• The company's ability to continue as a going concern is dependent on obtaining additional capital resources.
• Future financing may cause significant dilution to existing stockholders.
• The company faces risks related to cybersecurity, data privacy, and potential regulatory actions in China.
• The enforceability of civil liabilities in China for U.S. securities law violations is uncertain.
• Potential delisting from U.S. stock exchanges if the company's auditor is not subject to PCAOB inspections.

Future Outlook

The company's future outlook is highly uncertain due to the continued absence of revenue and significant operating losses. Management plans to secure additional capital from shareholders and third-party financing to continue operations. A 12-month financial support letter from a major shareholder provides some short-term liquidity assurance.

Management Comments

• The Company has continued to conduct market research and evaluation, including assessment of market outlook, risk factors and compliance considerations.
• The Company has also been actively exploring more effective sales approaches and distribution channels.
• Management's plan is to obtain such resources for the Company by obtaining capital from management and significant shareholders sufficient to meet its operating expenses and seeking third party equity and/or debt financing.

Industry Context

StockSavvy.ai notes that the biotech industry, particularly companies focused on stem cell technology, often requires substantial R&D investment and faces long development cycles. However, Yubo International Biotech's persistent lack of revenue and ongoing losses, even with reduced operating expenses, are concerning indicators, especially given the complex regulatory environment in China for such ventures.

Comparison to Industry Standards

• Companies in the stem cell research and development sector typically aim to generate revenue from product sales or licensing agreements within a reasonable timeframe after initial R&D phases.
• Biotech firms often require significant capital infusions, but successful ones demonstrate progress towards commercialization or have clear pathways to revenue generation.
• Competitors in the health and personal care product market, which Yubo Beijing also operates in, generally show consistent sales and revenue streams.
• The lack of revenue and ongoing losses for Yubo International Biotech are significantly below the performance expected for companies in the biotech and health product sectors that are beyond the very early-stage R&D phase.

Legal Proceedings

• We are currently not a party to any material legal or administrative proceedings.

Related Party Transactions

• On July 23, 2025, Yubo New York entered into a Securities Purchase Agreement with FlyDragon and ChinaOne, involving the sale of Class A Common Stock in exchange for the cancellation of shareholder loans due to Jun Wang and Yang Wang.

Stakeholder Impact

• Shareholders face significant risk of dilution from future capital raises and potential loss of investment if the company cannot continue as a going concern.
• Creditors and suppliers may face uncertainty regarding timely payment due to the company's going concern issues, although a shareholder support letter offers some assurance for the next 12 months.
• Employees may be concerned about job security given the company's financial instability and lack of revenue.

Next Steps

• Continue market research and evaluation of market outlook, risk factors, and compliance considerations.
• Actively explore more effective sales approaches and distribution channels.
• Obtain additional capital resources through management, significant shareholders, and third-party equity/debt financing.
• Continue to meet liabilities with financial support from Jun Wang for the next 12 months.

Key Dates

Recommendation

The company exhibits severe financial distress with no revenue, significant and increasing losses, and substantial doubt about its ability to continue as a going concern. Despite cost reductions and a shareholder support letter, the fundamental lack of a viable business model generating revenue makes it a high-risk investment. The VIE structure also introduces significant regulatory risks specific to China.

Keywords

VIE structure, going concern, operating loss, China regulations, biotech, stem cells, financial support, revenue generation